Erythropoietin Twenty to thirty per cent of people given recombinant human erythropoietin to correct anaemia in malignancies and end-stage renal disease may have hypertension induced or exacerbated within 2 to 16 weeks of starting treatment. The gene discussed is EPO; the disease is hypertensive disorder.